Primary Biliary Cholangitis | Treatment Algorithms: Claims Data Analysis | US | 2023
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is followed by cholestasis, which causes debilitating fatigue and itch, among other symptoms. Without adequate management, PBC culminates in liver fibrosis, cirrhosis, end-stage organ disease, and death. Currently, there is no cure for PBC. The goal of treatment is to halt or slow the progression of liver disease, reduce the need for liver transplantation, lower the risk of mortality, and alleviate symptoms. Ursodeoxycholic acid (UDCA) is the cornerstone of PBC treatment, and Intercept’s Ocaliva (obeticholic acid) is an option for patients who respond inadequately or cannot tolerate UDCA. Although these drugs improve outcomes, they do not address the underlying autoimmune defect or meaningfully improve symptoms. This analysis of U.S. patient-level claims data explores the use of UDCA, Ocaliva, and numerous symptomatic treatments in both newly diagnosed and recently treated patients, providing insight into the current treatment paradigm for PBC.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PBC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PBC patients?
- How has Ocaliva been integrated into the treatment algorithm, and what is its source of business?
- What percentage of PBC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PBC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Ursodeoxycholic acid (UDCA), Ocaliva (obeticholic acid), antiepileptic drugs, antihistamines, fibrates, oral corticosteroids, oral immunosuppressants, serotonin receptor antagonists, selective serotonin reuptake inhibitors (SSRIs), statins
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
